<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182581</url>
  </required_header>
  <id_info>
    <org_study_id>PGC0008</org_study_id>
    <nct_id>NCT04182581</nct_id>
  </id_info>
  <brief_title>A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Study of B-cell Maturation Antigen/Cluster of Differentiation Antigen 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an early, open, single-centered trial. The purpose of this study is to evaluate&#xD;
      the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or&#xD;
      refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment related AE</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of DLT</measure>
    <time_frame>12 weeks</time_frame>
    <description>Dose-limiting toxicity (DLT) will be collected. DLT refers to toxicity that limit the process to continue increasing CAR-T dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CAR copies concentration in peripheral blood</measure>
    <time_frame>2 years</time_frame>
    <description>CAR copies in peripheral blood will be measured by qPCR and FCM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>2 years</time_frame>
    <description>Objective response rate (ORR) will be calculated. ORR refers to the proportion between the number of subjects who are evaluated as PR or status better than PR and total number of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>2 years</time_frame>
    <description>Duration of response (DOR) will be calculated. DOR refers to the time between the initial response (CR or PR) to therapy and evaluated as PD for the first time or death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival (PFS) rate will be calculated. PFS refers to the proportion between the number of subjects who are evaluated as PD or died and total number of subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS) rate will be calculated. OS refers to the proportion between the number of subjects who died and total number of subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CAR-T treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive one dose of BCMA/CD19 dual-target CAR-T. BCMA/CD19 dual-target CAR-T dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCMA/CD19 Dual-Target CAR-T</intervention_name>
    <description>BCMA/CD19 Dual-Target CAR-T target both BCMA and CD19. The subjects will receive CAR-T as one dose. The dosage ranges from 5×10^4 to 3×10^5 CAR+T/Kg.</description>
    <arm_group_label>CAR-T treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-70 years;&#xD;
&#xD;
          2. Diagnosis of relapsed or refractory multiple myeloma(MM): 1) measurable disease at&#xD;
             screening as defined by any of the following: serum monoclonal paraprotein (M-protein)&#xD;
             level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or light chain MM without&#xD;
             measurable disease in the serum or the urine: serum immunoglobulin free light chain&#xD;
             ≥10 mg/dL and abnormal serum immunoglobulin kappa/lambda free light chain ratio. Light&#xD;
             chain MM without measurable disease in the serum or the urine is a specific definition&#xD;
             in this study, which refers to subjects whose M-protein in the serum and M-protein in&#xD;
             the urine is undetectable; 2) received at least 2 standard regimens, determined as&#xD;
             progressive disease (PD) by IMWG criteria; received at least 3 prior lines of&#xD;
             treatment for MM, undergone at least 1 complete cycle of treatment for each line,&#xD;
             unless PD was documented by IMWG criteria as the best response to the regimen; 3)&#xD;
             received a proteasome inhibitor(PI) and an immunomodulatory therapy (IMiD); 4)&#xD;
             documented disease progression during, or within 12 months of, most recent&#xD;
             anti-myeloma therapy.&#xD;
&#xD;
          3. Histologically confirmed positive expression of CD19 and/or BCMA 3 months prior to&#xD;
             enrollment;&#xD;
&#xD;
          4. Eastern cooperative oncology group (ECOG) performance status of 0 to 1;&#xD;
&#xD;
          5. Adequate organ function is defined as: 1) hemoglobin≥8.0g/dL(did not receive red blood&#xD;
             cell transfusion ≤7 days prior to laboratory tests; recombinant human erythropoietin&#xD;
             is allowed); 2) platelet count &gt;50×10^9/L(did not receive blood transfusion ≤7 days&#xD;
             prior to laboratory tests); 3) ANC ≥0.75×10^9/L(did not receive supportive treatment&#xD;
             ≤7 days prior to laboratory tests; growth factors are allowed); 4) total bilirubin&#xD;
             &lt;2×ULN (for subjects with congenital hyperbilirubinemia such as Gilbert's syndrome,&#xD;
             direct bilirubin≤1.5×ULN); 5) creatinine clearance (according to MDRD formulas or 24h&#xD;
             urine collection result) ≥40 mL/min/1.73m^2; 6) ALT and AST &lt;3×ULN; 7) corrected serum&#xD;
             calcium ≤12.5 mg/dL (≤3.1 mmol/L), or free calcium ion ≤6.5 mg/dL(≤1.6 mmol/L); 8)&#xD;
             oxygen saturation &gt;92% on non-oxygen-assistance state;&#xD;
&#xD;
          6. Females of childbearing potential must have a negative serum hypersensitive β-human&#xD;
             chorionic gonadotropin (β-hCG) or urine pregnancy test result, at screening, and prior&#xD;
             to lymphodepletion;&#xD;
&#xD;
          7. Females of childbearing potential must agree to use a highly effective contraception&#xD;
             continuously from signing informed consent form until ≥100 days after CAR-T infusion&#xD;
             (when continuously correctly used, failure rate &lt;1% per year). Highly effective&#xD;
             contraception include, user-independent method: 1) implantable progesterone&#xD;
             contraceptives which can inhibit ovulation; 2) intrauterine device (IUD); Intrauterine&#xD;
             hormone release system; 3) partner has a vasectomy; user-dependent method: 1) compound&#xD;
             hormone contraceptives which can inhibit ovulation (contain estrogen and progesterone,&#xD;
             oral/vaginal/transdermal administration); 2) progesterone contraceptives which can&#xD;
             inhibit ovulation (oral administration or injection);&#xD;
&#xD;
          8. Except for highly effective contraception, males must agree to use barrier&#xD;
             contraception (such as condom plus spermicidal foam/gel/film/suppository) during&#xD;
             sexual contact with a female of childbearing potential, to use condom during sexual&#xD;
             contact with a pregnant female, from signing informed consent form until ≥100 days&#xD;
             after CAR-T infusion; females and males must agree to avoid ovum/oocyte/sperm&#xD;
             donation, during the study period and ≥100 days after CAR-T infusion. Note: hormone&#xD;
             contraceptives may interact with the study treatment, thus reducing the contraceptive&#xD;
             effect;&#xD;
&#xD;
          9. Subject must sign an inform consent form indicating that he or she understands the&#xD;
             purpose of and procedures required for the study and is willing to participate in the&#xD;
             study. Consent is to be obtained prior to the initiation of any study-related tests or&#xD;
             procedures that are not part of standard-of-care for the subject's disease;&#xD;
&#xD;
         10. Willing and able to adhere to the prohibitions and restrictions specified in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of CAR-T treatment, the target of CAR-T is not limited;&#xD;
&#xD;
          2. History of anti-CD19 or anti-BCMA treatment;&#xD;
&#xD;
          3. Concomitant invasive malignancy other than diagnosis or treatment of other&#xD;
             radically-cured malignancies without malignant change ≥3 years prior to enrollment or&#xD;
             adequately- treated non-melanoma skin cancer without malignant change evidence;&#xD;
&#xD;
          4. Received targeted therapy, epigenetic therapy, experimental drug therapy, or&#xD;
             experimental invasive medical device &lt;14 days or 5 half-lives (according to the&#xD;
             shorter one) prior to leukapheresis; received monoclonal antibody &lt;21 days prior to&#xD;
             leukapheresis; received cytotoxic chemotherapy, PI, radiotherapy &lt;14 days prior to&#xD;
             leukapheresis (for radiotherapy, if the radiation field is no more than 5% of bone&#xD;
             marrow reserve, whenever radiotherapy ended, the subject is allowed to participate in&#xD;
             the study); received IMiD &lt;7 days prior to leukapheresis;&#xD;
&#xD;
          5. Toxicities related to prior therapy did not relieve to baseline or ≤ grade 1, except&#xD;
             for peripheral neuropathy and alopecia;&#xD;
&#xD;
          6. The following cardiac conditions: New York Heart Association(NYHA) grade III or IV&#xD;
             congestive heart failure; myocardial infarction or coronary artery bypass graft (CABG)&#xD;
             ≤6 months prior to enrollment; history of clinically significant ventricular&#xD;
             arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to&#xD;
             dehydration; history of severe non-ischemic cardiomyopathy; impaired cardiac function&#xD;
             (LVEF &lt;45%) as assessed by echocardiogram or multiple-gated acquisition (MUGA) scan&#xD;
             (performed ≤ 8 weeks prior to leukapheresis);&#xD;
&#xD;
          7. Systemic or local corticosteroid therapy of greater than 5 mg/day of prednisone (or&#xD;
             equivalent dose of another corticosteroid) within 2 weeks prior to leukapheresis;&#xD;
&#xD;
          8. Received either of the following: an allogeneic stem cell transplant for MM; an&#xD;
             autologous stem cell transplant ≤ 12 weeks prior to leukapheresis;&#xD;
&#xD;
          9. Known active central nervous system (CNS) involvement or emergence of meninges&#xD;
             involvement clinical signs;&#xD;
&#xD;
         10. Stroke or convulsions ≤ 6 months prior to ICF signing;&#xD;
&#xD;
         11. Presence of plasma cell leukemia(plasma cell &gt;2.0×10^9/L), Waldenstrom's&#xD;
             macroglobulinemia, POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy,&#xD;
             monoclonal protein disease, skin changes) or primary amyloidosis(AL) at screening;&#xD;
&#xD;
         12. Seropositive for human immunodeficiency virus (HIV); Hepatitis B infection as defined&#xD;
             according to the American Society of Clinical Oncology (ASCO) guidelines. In the event&#xD;
             the infection status is unclear, quantitative levels are necessary to determine the&#xD;
             infection status. Hepatitis C (anti-hepatitis C virus [HCV] antibody positive or&#xD;
             HCV-RNA quantitation positive) or known to have a history of hepatitis C;&#xD;
&#xD;
         13. Attenuated live vaccine ≤4 weeks prior to enrollment;&#xD;
&#xD;
         14. Known life threatening allergies, hypersensitivity, or intolerance to CAR-T cells or&#xD;
             its ingredients, including dimethylsulfoxide;&#xD;
&#xD;
         15. Serious underlying medical condition, such as: evidence of serious active viral,&#xD;
             bacterial, or uncontrolled systemic fungal infection; active autoimmune disease or a&#xD;
             history of autoimmune disease within 3 years; overt clinical evidence of dementia or&#xD;
             altered mental status; hereditary bleeding/ coagulating disease, a history of&#xD;
             non-traumatic bleeding or thromboembolism, other disease that may increase bleeding&#xD;
             risk;&#xD;
&#xD;
         16. Presence of any problems that may be detrimental to the subjects' receiving/tolerating&#xD;
             planned treatment and the subject's understanding ICF; presence of any condition that&#xD;
             the investigators think it is inappropriate for the subject to anticipate the trial&#xD;
             (such as damaging health); presence of any condition that may deter, limit, or&#xD;
             obfuscate protocol-defined evaluation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiequn Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First affiliated hospital of air force military medical university(i.e., Xijing Hopital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiequn Chen, Doctor</last_name>
    <phone>84771857</phone>
    <email>xiequnchen@fmmu.end.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital of air force military medical university(i.e., Xijing Hopital)</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiequn Chen, Doctor</last_name>
      <phone>84771857</phone>
      <email>xiequnchen@fmmu.end.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

